

CustomANALYTICS

AmerisourceBergen



Identify Opportunities for Product Differentiation and Expansion

Based on your unique business and clinical needs, IntrinsicQ Specialty Solutions™ can help you identify drug utilization trends, sales opportunities and potential competitive threats to your product. Our CustomANALYTICS solutions give you greater potential for product differentiation and expansion.

Life sciences companies benefit from IntrinsicQ Specialty Solutions' ability to aggregate and analyze substantial amounts of market information, gathered from a variety of sources including healthcare institutions, academia and health systems, as well as community-based practices and specialty pharmacies. Our significant analytical reach provides us with data on more than 13 million specialty patients, giving you definitive drug market insight into sales trends and opportunities, usage and uptake realities, as well as prescribing patterns and behaviors.

Forecast usage and uptake trends

Using a custom selection of our proprietary data sources and types, our CustomANALYTICS leverage a consultative, proactive, solution-oriented approach to help you understand prescribing patterns to improve usage and uptake of your drug.

- Identify sites and physicians with the most opportunity to benefit from a product by understanding their existing patient population and treatment decisions
- Characterize the scale of treatment opportunity by analyzing treatment volumes, sequencing, durations and dosing
- Pinpoint competitive threats to your product
- Assess the current state of your product and enhance baseline segmentation and targeting with a historical look back

Understand prescribing behavior and patterns

Our Opportunity and Risk Assessment analysis combines metrics on how recently, how often and how much product is purchased and/or used by providers. Go beyond your therapy and effectively evaluate competitive products and product adoption predictors to help develop meaningful targeting and segmenting tools. Increase promotion success and empower your business to spend your budget in the right way and on the right customers.

Health Economics and Outcomes Research

Demonstrate clinical and economic evidence to providers, healthcare decision makers and payers with custom studies of real-world evidence. In collaboration with Xcenda®, we can leverage our combined data assets to maximize the evidence and demonstrate the value of your product.

Data Assets:


- Aggregated de-identified data
- Medical and pharmacy claims
- Resource utilization

Benefits:

- Geographic diversity
- Sample size maximization
- Study replication
- Study feasibility

Study Opportunities:

- Provider insights
- Patient insights
- Payer insights
- Prospective/pragmatic studies



	Odds Ratio (95% Confidence Interval)		
	HEC	MEC	LEC
First-administration CINV event (ref: no first-administration CINV event)	3.70 (2.08-4.74)*	3.77 (3.04-4.68)*	3.05 (2.03-4.46)*
Number of chemotherapy administrations	1.03 (1.00-1.06)	1.04 (1.03-1.06)*	1.05 (1.03-1.06)*
Number of days between two chemotherapy administrations	0.98 (0.96-1.00)*	0.98 (0.97-0.99)*	0.98 (0.98-0.99)*
Female (ref: male)	1.25 (0.95-1.69)	1.15 (0.95-1.35)	1.20 (1.02-1.37)*
Age	1.00 (0.99-1.01)	1.00 (0.99-1.00)	0.99 (0.99-1.00)
Charlson comorbidity index	1.03 (0.95-1.11)	1.04 (0.95-1.09)	1.07 (1.01-1.13)*
Multi-cancer (ref: not multi-cancer)	0.95 (0.57-1.58)	0.87 (0.63-1.20)	1.20 (0.74-2.10)
Digestive cancer (ref: breast cancer)	2.99 (1.09-8.08)*	1.53 (1.21-1.92)*	1.90 (1.49-2.56)*
Genital cancer (ref: breast cancer)	1.87 (0.55-6.40)	0.92 (0.68-1.26)	1.65 (1.07-2.53)*
Lympho/hematologic cancer (ref: breast cancer)	0.75 (0.55-1.01)	0.44 (0.25-0.79)*	1.96 (1.31-2.83)*
Respiratory cancer (ref: breast cancer)	1.21 (0.60-1.96)	1.14 (0.70-1.44)	1.24 (0.76-2.01)
Other cancer (ref: breast cancer)	1.73 (1.11-2.72)*	1.27 (0.95-1.70)	1.54 (0.95-2.52)

CINV = chemotherapy-induced nausea and vomiting; HEC = highly emetogenic chemotherapy; LEC = low emetogenic chemotherapy; MEC = moderately emetogenic chemotherapy; SD = standard deviation.

*p < 0.05.

Data Source: This study was a retrospective, observational analysis of electronic medical records (EMR) data from April 1, 2006 through July 31, 2009.

IntrinsicQ Specialty Solutions has access to actionable data and analytics from thousands of healthcare institutions including academia, hospitals, community-based care and specialty pharmacies. By collaborating with our AmerisourceBergen sister companies—Xcenda, Lash Group and US Bioservices—we provide the necessary information for every aspect of your business from licensing and R&D, to pricing and market access strategies, to dictating research, planning and sales strategies.

To learn more, visit www.intrinsicqanalytics.com or email us at analyticalsales@intrinsicq.com.